iPSC-Derived Platelet Drug Delivery With Reduced Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets are limited by donor shortages, functional variability, and inefficiencies in delivering therapeutic drugs, particularly protein-based therapeutics, with nanoparticle approaches failing to achieve targeted delivery and causing adverse immune responses.
Innovation Solution
The development of induced pluripotent stem cell (iPSC)-derived megakaryocytic progenitors, megakaryocytes, proplatelets, and platelets, which can be loaded with therapeutic agents through receptor-mediated, passive, or covalent conjugation methods, and are engineered to enhance thrombin generation and minimize immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nanoparticle-based approaches are used for drug delivery, then enhanced permeability and retention effects are achieved, but adverse immune responses occur and repeated injections become compromised
Solution Approach 1:
The patent uses platelets as intermediary carriers to deliver therapeutic agents. Platelets naturally circulate in the bloodstream and can be engineered to carry drugs, proteins, or nucleic acids to target sites without triggering the same immune responses as synthetic nanoparticles. The platelet membrane serves as a biocompatible intermediary that protects the therapeutic cargo while avoiding immune recognition.
Solution Approach 2:
The patent changes the fundamental parameter of the delivery vehicle from synthetic nanoparticles to biological platelets. This parameter change transforms the delivery system from one that triggers immune responses to one that is naturally tolerated by the body, while maintaining the ability to achieve targeted delivery through physiological processes.
2Manufacturing precision
If nanoparticle approaches are used, then tissue-targeted delivery is attempted, but less than 1% of injected nanoparticles accumulate in targeted sites
Solution Approach 1:
The patent leverages the self-service capability of platelets to achieve targeted delivery. Platelets naturally respond to physiological signals at injury or disease sites, autonomously navigating to target locations without requiring complex external guidance systems. This self-service mechanism enables significantly higher accumulation at target sites compared to passive nanoparticle delivery.
Solution Approach 2:
The patent employs platelets that can perform multiple functions: they can carry various types of therapeutic agents (small molecules, proteins, nucleic acids), respond to different physiological signals, and deliver to diverse target sites. This multi-functionality makes the delivery system universally applicable across different disease indications while maintaining high targeting efficiency.
3Quantity of substance
If protein-based therapeutics are packaged in nanoparticles, then delivery is attempted, but the larger size of proteins prevents successful packaging
Solution Approach 1:
Instead of attempting to fit large protein therapeutics into small synthetic nanoparticle containers, the patent inverts the approach by using naturally large biological carriers (platelets) that are already sized appropriately to accommodate protein cargo. This inversion eliminates the packaging size constraint while maintaining delivery capability.
Solution Approach 2:
The patent creates a composite delivery system where therapeutic proteins are integrated with platelet structures. The platelet serves as a biological container that naturally accommodates and protects protein therapeutics, combining the structural integrity of the platelet with the therapeutic function of the protein cargo.
4Reliability
If donor platelets are used, then transfusion is performed, but wide functional variability between donor platelets limits transfusion effectiveness
Solution Approach 1:
The patent creates standardized platelet products through controlled differentiation of induced pluripotent stem cells (iPSCs). This copying process produces genetically identical platelets with consistent functional properties, eliminating the variability inherent in donor-derived platelets. The standardized platelets can be manufactured to specification and stored for on-demand use.
Solution Approach 2:
The patent performs preliminary action by deriving and banking platelets from iPSCs before they are needed for transfusion. This allows for standardization, quality control, and storage of platelet products in advance, ensuring consistent functionality when transfusion is required without relying on variable donor platelets.
5Quantity of substance
If platelet supply is increased to meet demand, then shortages are addressed, but limited platelet unit inventory is rapidly depleted in emergencies
Solution Approach 1:
The patent enables continuous production of platelets through iPSC differentiation. Rather than relying on finite donor supplies that deplete over time, the iPSC-based system can continuously generate new platelet units as needed. This continuous production capability ensures sustained availability during emergencies without rapid inventory depletion.
Solution Approach 2:
The patent implements a system where used or expired platelet products are discarded, but the underlying iPSC inventory is recovered and reused to produce new platelet units. This recovering approach allows the same stem cell line to generate multiple batches of platelets, effectively extending the durability of the platelet supply system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables on-demand production of well-defined platelet units with improved thrombin generation and targeted drug delivery, reducing donor shortages and adverse immune responses.
Implementation Method 1
the population of platelets derived from induced pluripotent stem cells exhibit increased thrombin generation relative to a population of donor derived platelets
Data Source
AI summary
Methods for producing megakaryoctyres and platelets derived from inducible pluripotent stem cells are provided. Such megakaryocytes or platelets can be genetically modified to comprise a nucleic acid molecule encoding a therapeutic agent. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.